ArticleProbiotics and antimicrobial proteins2026
Bile Salt Hydrolase Activity in the Food-Derived Strain Levilactobacillus brevis M3R3: Genomic and Functional Characterization.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in research on the effects of bile acids and their receptors on intestinal function.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In the present study, Levilactobacillus brevis M3R3, isolated from traditional Sicilian sourdough, was evaluated for bile salt hydrolase (BSH) activity through kinetic growth assays and bile salts (BSs) deconjugation analysis by UHPLC/HR-MS. Genome sequencing and in silico analyses were performed to assess its safety and probiotic potential. Results showed that strain M3R3 tolerated different concentrations of individual conjugated BSs, with dose-dependent growth inhibition. Exposure to 1.0% glycocholic and glycodeoxycholic acids reduced M3R3 growth, indicating an adaptive stress response. When exposed to a mixed BS solution mimicking intestinal conditions, the strain maintained growth despite an extended lag phase and a reduced final biomass, likely due to toxic BSs accumulation. UHPLC/HR-MS confirmed complete deconjugation of glyco-conjugated BSs and partial deconjugation of tauro-conjugated BSs. Whole-genome sequencing (2.30 Mbp, 2375 CDSs) revealed absence of antimicrobial resistance or virulence genes and identified two bsh genes (bsh_2A and bsh_3A), both expressed under control and BS-exposed conditions. Phylogenetic analysis of L. brevis BSH proteins identified three clusters (I, II, and III), with bsh_2A and bsh_3A from M3R3 grouped in clusters II and III, respectively. Overall, genomic and functional characterizations support that L. brevis M3R3 is a safe, BSH-active strain, with potential applications as a functional ingredient in health promoting formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.